TRCT
SION

Tower Research Capital (TRC)’s Sionna Therapeutics SION Stock Holding History

Tower Research Capital (TRC)’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.3K Sell
1,279
-1,073
-46% -$42.9K ﹤0.01% 2634
2026
Q1 		$94.3K Buy
2,352
+1,223
+108% +$46.7K ﹤0.01% 2232
2025
Q4 		$46.4K Sell
1,129
-3,361
-75% -$127K ﹤0.01% 2478
2025
Q3 		$132K Buy
+4,490
New +$97.7K ﹤0.01% 1792

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Tower Research Capital (TRC)'s SION Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Sionna Therapeutics (SION) stake by 46% in Q2 2026, selling an estimated $42.9K and leaving 1,279 shares worth $56.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2634.

Tower Research Capital (TRC) first reported a position in SION in Q3 2025 and has held it in 4 quarters since. The position peaked at $132K in Q3 2025. 146 funds tracked by Wall St. Rank hold SION as of Q2 2026.

  • Tower Research Capital (TRC) held 1,279 shares of Sionna Therapeutics worth $56.3K as of Q2 2026.
  • Tower Research Capital (TRC) sold 1,073 Sionna Therapeutics shares in Q2 2026, an estimated $42.9K.
  • Sionna Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2634 holding.
  • Tower Research Capital (TRC) first reported a position in Sionna Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Tower Research Capital (TRC)'s Sionna Therapeutics position peaked at $132K in Q3 2025.
  • 146 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.